Florida is currently home to 3753 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Long Term Follow up of Recipients of Functional Islet Allografts
Recruiting
Since its inception, the Diabetes Research Institute (DRI) has made significant contributions to the field of diabetes, pioneering many of the techniques used in diabetes centers around the world. Through several clinical trials, DRI has demonstrated that diabetes can be successfully reversed as a result of islet cell transplant. Over the years the following protocols in islet cell transplantation have been initiated: 2000/0329; 2000/0196; 2004/0205; 2000/024; 2006/0200; 2006/0508; 2006/0210.... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/24/2025
Locations: Diabetes Research Institute, Miami, Florida
Conditions: Type 1 Diabetes Mellitus
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
Recruiting
This is a single-center, prospective, open label study in islet transplant recipients after complete islet graft rejection/loss, defined as stimulated c-peptide ≤0.3 ng/mL.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
01/24/2025
Locations: Diabetes Research Institute, Miami, Florida
Conditions: Type 1 Diabetes Mellitus
Collecting Medical Information and Tissue Samples from Patients with Pancreatic Cancer or Other Pancreatic Disorders
Recruiting
RATIONALE: Gathering medical information and collecting and storing samples of blood and tissue to test in the laboratory may help doctors develop better ways to screen people at risk for pancreatic cancer or other pancreatic disorders in the future. PURPOSE: This clinical trial is collecting medical information and tissue samples from patients with pancreatic cancer or other pancreatic disorders.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Islet Cell Tumor, Pancreatic Cancer, Pancreatic Disease, Acute Pancreatitis, Chronic Pancreatitis, Hereditary Pancreatitis, Pancreatic Neuroendocrine Carcinoma
Multicenter ALS Imaging Study
Recruiting
This is a multi-site study of ALS participants and healthy controls who will undergo brain and cervical spine MRIs and NfL blood testing at up-to 4 time points over the course of a year. The primary goal is to identify objective biomarkers of disease progression that are biologically relevant, linearly progressive, and sensitive to change.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Amyotrophic Lateral Sclerosis, ALS
Psilocybin for Major Depressive Disorder (MDD)
Recruiting
Approximately 240 eligible adult participants (≥18 years old) who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) criteria for Major Depressive Disorder (MDD) will be enrolled. Participants will be randomly assigned to receive a single oral dose of Psilocybin 25 mg, Psilocybin 5 mg, or inactive placebo. The purpose of this study is to evaluate the efficacy, safety, and tolerability of Psilocybin 25 mg versus placebo in adults with MDD, as assessed by the difference between... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: Clinical Neuroscience Solutions Inc., Jacksonville, Florida
Conditions: Depressive Disorder, Major
A Study to Evaluate the Safety of CMTX-101 in People with Cystic Fibrosis
Recruiting
CMTX-101 is a bacterial biofilm disrupting monoclonal antibody being developed as an adjunctive therapy to standard of care antibiotics. The goal of this clinical trial is to assess the safety and tolerability of CMTX-101 in people with cystic fibrosis (pwCF). The main questions the study aims to answer are: * Are single doses of CMTX-101 IV infusion safe and tolerated * What is the pharmacokinetic (PK) profile of single doses of CMTX-101 * Do single doses of CMTX-101 induce development of ant... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: Central Florida Pulmonary Group, PA, Orlando, Florida
Conditions: Persistent Infection, Cystic Fibrosis
Fast Induced Remodeling in Heart Failure with Preserved Ejection Fraction
Recruiting
FIRE-HFpEF is a multi-center, prospective, randomized, single-blinded, clinical feasibility study. This study will enroll up to 105 subjects with heart failure with preserved ejection fraction in the United States. Data will be collected to evaluate whether pacing therapies can lead to improvements in exercise capacity and health status of subjects.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: NCH Heart Institute, Naples, Florida
Conditions: Heart Failure With Preserved Ejection Fraction, Concentric Hypertrophy
Integrated Care and Treatment for Severe Infectious Diseases and Substance Use Disorders Among Hospitalized Patients
Recruiting
The goal of this clinical trial is to test the effectiveness of an integrated infectious disease/substance use disorder (SUD) clinical team intervention approach in patients hospitalized with severe injection-related infections (SIRI) who use drugs. The main question this study aims to answer is whether this intervention approach will be associated with lower mortality and fewer hospital readmissions. Participants will participate in the integrated SUD/ID care team intervention (SIRI Team). Rese... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: University of Miami - Jackson Memorial Hospital, Miami, Florida
Conditions: Injection Site Infection, Substance Use Disorders
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
Recruiting
In this first-in human, phase I/IIa study, the safety and efficacy of \[212Pb\]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in combination with Nivolumab in subjects with unresectable and metastatic melanoma.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
01/23/2025
Locations: Biogenix Molecular, Miami, Florida
Conditions: Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Mucosal Melanoma, Melanoma Stage III
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Women With a PI3K Alteration and HR+/Her2- Breast Cancer
Recruiting
This is a Phase 1b/2, open-label, parallel-arms pilot study in post-menopausal women with hormone receptor positive (HR+), HER2- advanced or metastatic breast cancer with an alteration in the PI3K pathway, including a mutation of the PIK3CA gene, PTEN loss, or AKT1 mutation, designed to determine the safety of evexomostat (SDX-7320) plus standard of care treatment alpelisib (BYL-719) or capivasertib and fulvestrant (each combined, the 'triplet therapy'), to measure the severity and number of hyp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: Miami Cancer Institute at Baptist Health, Miami, Florida
Conditions: HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer
Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters
Recruiting
Single-arm, prospective study assessing semen quality after treatment with the Optilume Urethral DCB in men between 22 and 65 years of age.
Gender:
MALE
Ages:
Between 22 years and 65 years
Trial Updated:
01/23/2025
Locations: Orlando Health, Orlando, Florida
Conditions: Urethral Stricture
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Recruiting
This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on only abiraterone by PCWG3 criteria prior to study entry. The patient population will be separated into two cohorts: Cohort A: Patients with poor response to prior abiraterone defined as: * Abiraterone started in hormone-sensitive prostate cancer (HSPC) dise... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: D&H Cancer Research Center, LLC, Margate, Florida
Conditions: Metastatic Castration-Resistant Prostate Cancer